CLC number:
On-line Access: 2023-06-26
Received: 2022-12-07
Revision Accepted: 2023-04-20
Crosschecked: 2023-09-26
Cited: 0
Clicked: 866
Qing QIU, Chenghao WU, Wenxiao TANG, Longfei JI, Guangwei DAI, Yuzhen GAO, Enguo CHEN, Hanliang JIANG, Xinyou XIE, Jun ZHANG. Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors[J]. Journal of Zhejiang University Science B, 2023, 24(10): 935-942.
@article{title="Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors",
author="Qing QIU, Chenghao WU, Wenxiao TANG, Longfei JI, Guangwei DAI, Yuzhen GAO, Enguo CHEN, Hanliang JIANG, Xinyou XIE, Jun ZHANG",
journal="Journal of Zhejiang University Science B",
volume="24",
number="10",
pages="935-942",
year="2023",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2200631"
}
%0 Journal Article
%T Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors
%A Qing QIU
%A Chenghao WU
%A Wenxiao TANG
%A Longfei JI
%A Guangwei DAI
%A Yuzhen GAO
%A Enguo CHEN
%A Hanliang JIANG
%A Xinyou XIE
%A Jun ZHANG
%J Journal of Zhejiang University SCIENCE B
%V 24
%N 10
%P 935-942
%@ 1673-1581
%D 2023
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200631
TY - JOUR
T1 - Development and validation of a risk-prediction model for immune-related adverse events in patients with non-small-cell lung cancer receiving PD-1/PD-L1 inhibitors
A1 - Qing QIU
A1 - Chenghao WU
A1 - Wenxiao TANG
A1 - Longfei JI
A1 - Guangwei DAI
A1 - Yuzhen GAO
A1 - Enguo CHEN
A1 - Hanliang JIANG
A1 - Xinyou XIE
A1 - Jun ZHANG
J0 - Journal of Zhejiang University Science B
VL - 24
IS - 10
SP - 935
EP - 942
%@ 1673-1581
Y1 - 2023
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200631
Abstract: Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males. Immune-checkpoint inhibitors (ICIs) that target programmed cell death protein-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) have achieved impressive efficacy in the treatment of non-small-cell lung cancer (NSCLC) (
[1]BiswasT, KangKH, GawdiR, et al., 2020. Using the systemic immune-inflammation index (SII) as a mid-treatment marker for survival among patients with stage-III locally advanced non-small cell lung cancer (NSCLC). Int J Environ Res Public Health, 17(21):7995.
[2]Castelo-BrancoC, SoveralI, 2014. The immune system and aging: a review. Gynecol Endocrinol, 30(1):16-22.
[3]ChampiatS, LambotteO, BarreauE, et al., 2016. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol, 27(4):559-574.
[4]CortelliniA, ChiariR, RicciutiB, et al., 2019. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer, 20(4):237-247.e1.
[5]CortelliniA, BersanelliM, SantiniD, et al., 2020. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur J Cancer, 128:17-26.
[6]DalyLE, PowerDG, O'ReillyÁ, et al., 2017. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer, 116(3):310-317.
[7]DeurenbergP, YapM, van StaverenWA, 1998. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes, 22(12):1164-1171.
[8]DoroshowDB, SanmamedMF, HastingsK, et al., 2019. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res, 25(15):4592-4602.
[9]DvorakHF, 2015. Tumor stroma, tumor blood vessels, and antiangiogenesis therapy. Cancer J, 21(4):237-243.
[10]EunY, KimIY, SunJM, et al., 2019. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep, 9:14039.
[11]GaoZR, LingX,Shi CYY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843.
[12]GeorgiadisMS, SteinbergSM, HankinsLA, et al., 1995. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst, 87(5):361-366.
[13]HuB, YangXR, XuY, et al., 2014. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res, 20(23):6212-6222.
[14]HuangYQ, SoonYY, AminkengF, et al., 2022. Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. Int J Cancer, 150(4):636-644.
[15]KugelCH III, DouglassSM, WebsterMR, et al., 2018. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res, 24(21):5347-5356.
[16]KumarV, ChaudharyN, GargM, et al., 2017. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol, 8:49.
[17]LiNL, 2016. Platelets in cancer metastasis: to help the “villain” to do evil. Int J Cancer, 138(9):2078-2087.
[18]MailletD, CorbauxP, StelmesJJ, et al., 2020. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer, 132:61-70.
[19]MantovaniA, AllavenaP, SicaA, et al., 2008. Cancer-related inflammation. Nature, 454(7203):436-444.
[20]MirsoianA, MurphyWJ, 2015. Obesity and cancer immunotherapy toxicity. Immunotherapy, 7(4):319-322.
[21]NishinoM, Giobbie-HurderA, HatabuH, et al., 2016. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol, 2(12):1607-1616.
[22]O'KaneGM, LabbéC, DohertyMK, et al., 2017. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist, 22(1):70-80.
[23]PardollDM, 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4):252-264.
[24]PawelecG, 2018. Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma? Clin Cancer Res, 24(21):5193-5194.
[25]PengLH, WangY, LiuF, et al., 2020. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother, 69(9):1813-1822.
[26]PuzanovI, DiabA, AbdallahK, et al., 2017. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 5(1):95.
[27]SongP, ZhangDD, CuiXX, et al., 2020. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer, 11(9):2406-2430.
[28]von ItzsteinMS, KhanS, GerberDE, 2020. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem, 66(6):779-793.
[29]WangQ, LiSB, QiaoSM, et al., 2021. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front Immunol, 12:648652.
[30]ZamoraC, RiudavetsM, AngueraG, et al., 2021. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. Cancer Immunol Immunother, 70(6):1691-1704.
Open peer comments: Debate/Discuss/Question/Opinion
<1>